that mimic UC and should be considered initially in elderly patients, which otherwise delay the appropriate treatment. The differential diagnoses include infections, ischemia, drug-related complications, and radiation colitis ( Table 2 ).
Infective colitis
Infective colitis is common in elderly people, which is difficult to differentiate from UC with concomitant bacterial infections, due to the endoscopic and histological findings that overlap with those of UC. 12 Aeromonas species and Clostridium difficile are common pathogens in chronic infective colitis and UC. 13 However, bloody diarrhea, decreased response to antibiotic treatment, and histological features of cryptitis and crypt abscess are important features in the diagnosis of UC with bacterial infection. 13 Cytomegalovirus (CMV) infection is common in elderly UC people with comorbidities (most commonly chronic renal insufficiency and diabetes mellitus) or who have been hospitalized for other conditions. The clinical presentations are diarrhea, hematochezia, tenesmus, abdominal pain, and bloody diarrhea.
14 The endoscopic appearance is usually nonspecific and limited to the left colon, which is indistinguishable from UC. 15 Three identified features were well-demarcated ulcerations, ulceroinfiltrative changes, and pseudomembrane formation. 16 Histological specimens of viral intranuclear inclusions (as owl's eye appearance) confirm the diagnosis. 17 
Ischemic colitis
Ischemic colitis (IC) occurs with greater frequency in elderly people, especially in patients with comorbidities of diabetes, dyslipidemia, heart failure, or peripheral arterial disease. 18 Compared with UC, features of IC are abrupt-onset abdominal pain, shortdisease course, and mild anemia. 19 Endoscopic findings which distinguish IC from UC are the segmental distribution, rectum sparing, and rapid resolution on serial examinations. 20 The definitive histology of IC include the detection of mucosal infarction, clots or fibrin in the capillaries, or submucosal hemorrhage. 
Drug-related colitis
Medications including nonsteroidal anti-inflammatory drugs (NSAIDs), estrogens, digitalis, and sodium phosphate (NaP) can induce colitis. 9 The most common drug is NSAID because it is widely used for arthritis and other painful conditions in elderly people. The common symptoms of drug-related colitis include abdominal pain, diarrhea, and blood in stools. The typical endoscopic appearance is sharply demarcated ulceration with adjacent normal mucosa. 22 The histology of NSAID-related colitis shows no evidence of chronic features (crypt distortion, basal plasmacytosis, Paneth metaplasia), and increasing mucosal eosinophils is a common feature in most drug-related colitis. 23 Oral NaP is widely used for bowel preparation for its good tolerability and effective bowel cleansing ability. However, NaP would cause colitis, especially in the distal colon and rectum. 24 The histologic findings range from edema, hemorrhage, and mononuclear infiltration to increased epithelial crypt proliferation and apoptosis. 25 
Radiation colitis
Radiation colitis is also common in the elderly population with a history of radiation over the lower pelvis, and the symptoms are diarrhea, urgency, bleeding, pain, or tenesmus. 26 Endoscopy can reveal friability and granularity, erythema, or prominent telangiectasias, which mimic UC. Classical histologic findings are epithelial meganucleosis and fibroblastic proliferation. 
Treatments
The treatment of UC in elderly patients is the same as that in younger patients; however, therapeutic approaches for UC in this unique population have been based on expert opinion and data extrapolated from clinical trials that may or may not have included elderly patients. 3, 10 The elderly population, independent of functional status, is often excluded due to comorbidities and polypharmacy and concern about drug interactions. 3, 10, 27 The treatment of UC depends on the severity and location of disease. 6 The goals of treatment are to induce and maintain remission, prevent complications, and improve the quality of life.
3,6
Aminosalicylate
The first-line therapy for elderly patients with mild to moderate UC is oral 5-aminosalicylate (5-ASA) (2.0-4.8 g/day).
1 Topical 5-ASA is an effective therapy for proctitis and left-sided colitis. The combination of oral and topical 5-ASA is more effective in extensive UC. 6 However, topical therapy in elderly patients presents special challenges relating to sphincter incompetence and poor coordination skills to self-administer. 28 5-ASA has a side effect of nephrotoxicity due to slower elimination of drugs and should be carefully administered to elderly patients with poor renal function or heart failure. 29 The risk of renal impairment is related to treatment duration and doses, and renal function would improve with discontinuation of the 5-ASA. 
Corticosteroids
Corticosteroids (maximum dose 1 mg/kg/day or 60 mg/day) are standard treatment in induce remission and severe UC. 6 Budesonide-MMX, a novel oral formulation with less systemic side effects, is recommended for mild to moderate UC. 6 However, steroid is not advised for use as maintenance treatment due to adverse events such as hypertension, hypokalemia, hyperglycemia, and mental status changes after long-term use in elderly patients. 3, 10 Osteoporosis-related fracture is an important issue in the elderly patients with IBD, and these patients require calcium, vitamin D, and possibly a bisphosphonate to minimize the complications. 31 
Immunosuppressants
Immunomodulators should be used in steroid-dependent patients for maintenance therapy. 6, 10 Data from the EPIMAD registry, including 841 patients aged over 65 years at IBD diagnosis, showed that 16% of UC patients received immunosuppressive agents after 10 years and only 3% received anti-TNF therapy. 1 The currently recommended immunosuppressant treatment is azathioprine (AZA) 1.0-2.5 mg/kg. 6 Adverse events associated with AZA include leukopenia, fever, pancreatitis, and hepatitis. In patients with hypertension, the angiotensin-converting-enzyme inhibitor should be avoided because its interaction with AZA may lead to leukopenia and anemia. 32 In elderly patients, male sex and longer duration of AZA treatment are risk factors of developing lymphoma. 33 
Biologic agents
Biologic agents are used in patients failing conventional therapies or who are steroid dependent. 
Anti-tumor necrosis a agents
Anti-TNF agents have become a significant treatment for UC, proving to induce clinical remission with rapid onset. 6 In elderly patients with UC, anti-TNF would increase the risk of opportunistic infection and mortality. 34 Older patients are threefold more likely to quit anti-TNF therapy compared to younger patients and twofold more likely to stop anti-TNF therapy compared to use of immunomodulators. 35 IFX is the first and most extensively studied biologic agent, however, there are fewer studies have focused on the safety of IFX in the elderly. 36, 37 Induction of IFX in acute severe UC is more efficacious than other biologics. 6, 36 In an IBD expert group consensus, IFX usage in patients older than 70 is not recommended but can be used as an alternative to surgery in severe UC. 37 ADA attain similar efficacy as IFX on long-term maintenance therapy. 36 ADA may be an appropriate option in older patients in whom monotherapy, rather than combination therapy with an immunomodulator. 6, 38 Recently, GOL has shown the same safety and efficacy profile as other anti-TNF agents. 38 
Anti-integrin agent
VDZ is a novel humanized monoclonal antibody to integrin that selectively inhibits inflammation in the gastrointestinal tract, suggesting lower risks of systemic toxicities and immunosuppression. 39, 40 This drug has a moderate effect and slow onset of action. 40 VDZ is safe in older patients; however, further large-scale and longterm follow-up studies are still required. [40] [41] [42] The risk factors for serious infection in VDZ are prior failure of anti-TNF and narcotic analgesic use. 43 
Surgical treatment
Bowel perforation, massive bleeding, toxic megacolon, severe colitis unresponsive to medical treatment, high-grade dysplasia, and carcinoma are indications for surgical treatment in patients with UC. 6 The risk of surgery among older patients is similar to that in younger patients. 10 Sphincter function needs to be carefully evaluated preoperatively if ileal-anal pouch surgery is intended. The incidence of anastomotic leaks and pouch-related complications ( Fig. 1 ) and pouch failure rates do not differ between younger and older patients. 44 Urgent surgery, low levels of albumin, and male sex are predictors of poor outcome in an elderly population. 45 The complication and death rates have decreased significantly over time with the advances in perioperative care.
44,45
Special consideration in elderly patients
Elderly patients with UC are at increased risk of developing colorectal cancers (CRC) (Fig. 2) , and the risk increased with the disease extent and duration. 6 Surveillance guidelines are based on colitis duration, and recommendations are not different for elderly patients. 3, 10 Colonoscopy in elderly patients carries a greater risk of complications, lower completion rates, and higher chance of poor bowel preparation. 46 The potential benefits are significantly decreased because of shorter life expectancy and greater preva-W.-C. Lin et al. lence of comorbidities in this group. Thus, screening colonoscopy in elderly patients should be performed only after careful consideration of the potential benefits and risks as well as patient preferences. 46 Patients with IBD treated with corticosteroids, immunomodulators, and biologic agents are at increased risk of developing infectious complications from immune suppression. Thus, elderly patients with additional comorbidities are more susceptible to infection. Verifying vaccination status and regularly vaccinating for influenza, hepatitis B virus, and pneumococcal disease are recommended. 47 
Conclusion
With the increasing prevalence of UC among older individuals, clinicians should take care of such specific group with high comorbidity rates and polypharmacy. Diagnosis may be difficult because there are numerous clinical conditions that may mimic UC and some elderly patients with UC present with atypical symptoms. The treatment should consider potential pharmacological interactions and focus on the side effects caused by advanced age.
